Pomeroy Benjamin, Venanzi Alexander W, Li Wei, Hackam Abigail S, Abdulreda Midhat H
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Biomedicines. 2023 Jan 20;11(2):293. doi: 10.3390/biomedicines11020293.
Diabetic retinopathy (DR) afflicts more than 93 million people worldwide and is a leading cause of vision loss in working adults. While DR therapies are available, early DR development may go undetected without treatment due to the lack of sufficiently sensitive tools. Therefore, early detection is critically important to enable efficient treatment before progression to vision-threatening complications. A major clinical manifestation of early DR is retinal vascular leakage that may progress from diffuse to more localized focal leakage, leading to increased retinal thickness and diabetic macular edema (DME). In preclinical research, a hallmark of DR in mouse models is diffuse retinal leakage without increased thickness or DME, which limits the utility of optical coherence tomography and fluorescein angiography (FA) for early detection. The Evans blue assay detects diffuse leakage but requires euthanasia, which precludes longitudinal studies in the same animals.
We developed a new modality of ratiometric fluorescence angiography with dual fluorescence (FA-DF) to reliably detect and longitudinally quantify diffuse retinal vascular leakage in mouse models of induced and spontaneous DR.
These studies demonstrated the feasibility and sensitivity of FA-DF in detecting and quantifying retinal vascular leakage in the same mice over time during DR progression in association with chronic hyperglycemia and age.
These proof-of-concept studies demonstrated the promise of FA-DF as a minimally invasive method to quantify DR leakage in preclinical mouse models longitudinally.
糖尿病视网膜病变(DR)在全球影响着超过9300万人,是在职成年人视力丧失的主要原因。虽然有DR治疗方法,但由于缺乏足够敏感的工具,早期DR发展在未治疗的情况下可能未被发现。因此,早期检测对于在进展为威胁视力的并发症之前进行有效治疗至关重要。早期DR的一个主要临床表现是视网膜血管渗漏,其可能从弥漫性发展为更局限的局灶性渗漏,导致视网膜厚度增加和糖尿病性黄斑水肿(DME)。在临床前研究中,小鼠模型中DR的一个标志是弥漫性视网膜渗漏,而无厚度增加或DME,这限制了光学相干断层扫描和荧光素血管造影(FA)用于早期检测的效用。伊文思蓝试验可检测弥漫性渗漏,但需要安乐死,这排除了在同一动物中进行纵向研究。
我们开发了一种具有双荧光的比率荧光血管造影新方法(FA-DF),以可靠地检测和纵向量化诱导性和自发性DR小鼠模型中的弥漫性视网膜血管渗漏。
这些研究证明了FA-DF在检测和量化DR进展过程中随时间推移同一小鼠视网膜血管渗漏方面的可行性和敏感性,该过程与慢性高血糖和年龄相关。
这些概念验证研究证明了FA-DF作为一种微创方法在临床前小鼠模型中纵向量化DR渗漏的前景。